BPC-157 vs GHK-Cu

Category

Molecular weight

1419.53 g/mol

340.38 g/mol

Half-life

~4 hours (stable in gastric juice — unique among peptides)

~1 hour (injectable); variable topical absorption

Admin routes

Research areas

Typical dosing

250–500 mcg · 1-2x daily · 4-12 weeks

200–500 mcg · 1x daily (injectable); 1-2x daily (topical) · 4-8 weeks (injectable); ongoing (topical)

FDA status

Not FDA-approved and NOT compoundable as of June 2026 (per regulatory-status-refresh-2026-06): removed from the Category 2 do-not-compound list in April 2026 (nomination withdrawn, effective 2026-04-23) — this is a procedural step, not approval, and BPC-157 is NOT Category 1. PCAC review scheduled Jul 23, 2026. Also WADA-prohibited (S0).

Not FDA-approved as drug. Available OTC in cosmetic formulations. NOT compoundable as of June 2026 (per regulatory-status-refresh-2026-06): injectable GHK-Cu removed from Category 2 and non-injectable GHK-Cu removed from Category 1 in April 2026 (nominations withdrawn) — PCAC review due by end of Feb 2027.

WADA status

Prohibited (S0 category — non-approved substances, effective January 2022)

Not prohibited (as of 2026)

PubMed studies

213

163